"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A1,EP 2152744 A1,027-391-421-265-578,2010-02-17,2010,EP 08743351 A,2008-04-28,US 2008/0005427 W;;US 92660507 P,2007-04-26,PRION PROTEIN AS A RECEPTOR FOR AMYLOID-BETA OLIGOMERS,,UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,,https://lens.org/027-391-421-265-578,Patent Application,yes,0,0,8,8,16,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,C07K16/28;;C07K16/00;;G01N33/53,,0,0,,,,DISCONTINUED
2,US,A1,US 2010/0291090 A1,169-864-434-182-364,2010-11-18,2010,US 59753508 A,2008-04-28,US 59753508 A;;US 92660507 P;;US 2008/0005427 W,2007-04-26,Prion Protein as a Receptor for Amyloid-Beta Oligomers,"The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinittions, as well as methods of identifying molecules that could function as PrP c antagonists.",STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,YALE UNIVERSITY (2009-11-16),https://lens.org/169-864-434-182-364,Patent Application,yes,2,9,8,8,0,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,A61K39/395;;A61K31/7088;;A61K38/00;;A61K38/10;;A61K38/12;;A61K38/16;;G01N33/53,424/139.1;;514/1.1;;X514 44  R;;424/130.1;;514/21.2;;514/21.5;;514/21.3;;514/21.1;;424/141.1;;X514 44  A;;435/7.1,8,6,000-110-003-485-005;;038-089-320-425-423;;047-212-737-657-235;;117-905-099-283-548;;043-568-251-456-160;;016-497-157-058-276,16817866;;pmc1779824;;10.1111/j.1460-9568.2006.04805.x;;17451912;;10.1016/j.bbadis.2007.02.011;;pmc1986710;;22137045;;10.1016/j.pneurobio.2011.11.008;;10.2165/00002512-200219070-00002;;12182685;;19829371;;pmc2810658;;10.1038/nature08538;;7659297;;10.1016/0304-3940(95)11565-7,"Pankiewicz et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci. 2006 May;23(10):2635-47.;;Zeisel et al. Non-pharmacological Treatment for Alzheimer's Disease: A mind-brain approach. Non-pharmacological Treatment for Alzheimer's. March 1999, p. 1-16.;;Westergard et al. The cellular prion protein (PrPc): Its physiological function and role in disease. Biochim Biophys Acta. 2007 June; 1772(6): 629-644.;;Hirsch et al. PrPc signalling in neurons: From basics to clinical challenges. Biochimie, in press, available online 18 June (2014) pp. 1-10.;;Hampel et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol. 2011 Dec;95(4):718-28.;;Vickers. A vaccine against Alzheimer's disease: developments to date. Drugs Aging. 2002;19(7):487-94. Review.;;Perrin et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009 Oct 15;461(7266):916-22.;;Golabek et al. ABSTRACT ONLY. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett. 1995 May 19;191(1-2):79-82.",ACTIVE
3,US,B2,US 9217036 B2,126-856-097-556-053,2015-12-22,2015,US 59753508 A,2008-04-28,US 59753508 A;;US 92660507 P;;US 2008/0005427 W,2007-04-26,Prion protein as a receptor for amyloid-β oligomers,"The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as PrP c antagonists.",STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID;;UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,YALE UNIVERSITY (2009-11-16),https://lens.org/126-856-097-556-053,Granted Patent,yes,3,1,8,8,18,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,C07K16/28;;A61K39/00,,49,43,000-110-003-485-005;;038-089-320-425-423;;047-212-737-657-235;;117-905-099-283-548;;043-568-251-456-160;;016-497-157-058-276;;031-829-159-115-790;;065-423-927-132-846;;053-553-449-696-849;;071-772-765-956-684;;030-631-215-273-217;;016-549-612-137-366;;059-971-084-679-981;;057-528-556-690-064;;001-201-895-754-484;;121-995-361-405-800;;079-004-710-947-368;;034-356-721-676-31X;;021-695-541-625-958;;013-184-902-837-362;;026-958-189-625-695;;010-513-380-716-971;;045-223-561-756-846;;045-680-003-786-657;;059-081-039-720-274;;045-153-912-389-523;;097-482-443-968-533;;020-871-857-662-177;;086-632-035-133-010;;091-280-552-703-792;;018-140-225-646-696;;051-393-096-432-799;;060-370-336-705-413;;016-355-076-521-392;;076-597-726-661-804;;026-785-408-221-883;;035-382-286-267-663;;047-618-142-023-137;;031-616-215-173-831;;000-110-003-485-005;;153-215-404-527-703;;003-156-271-477-135;;013-804-064-203-989,16817866;;pmc1779824;;10.1111/j.1460-9568.2006.04805.x;;17451912;;10.1016/j.bbadis.2007.02.011;;pmc1986710;;22137045;;10.1016/j.pneurobio.2011.11.008;;10.2165/00002512-200219070-00002;;12182685;;19829371;;pmc2810658;;10.1038/nature08538;;7659297;;10.1016/0304-3940(95)11565-7;;pmc1904148;;17573534;;10.1073/pnas.0609621104;;10.1006/nbdi.1997.0130;;9173930;;17245436;;10.1038/sj.emboj.7601510;;pmc1783444;;1373228;;10.1038/356577a0;;10.1038/6374;;10195221;;10.1038/35050103;;11140684;;14596589;;10.1021/bi030029q;;15608634;;10.1038/nn1372;;10.1038/35053072;;11201742;;10.1038/nrm2101;;17245412;;12130773;;10.1126/science.1072994;;14645205;;10.1093/hmg/ddh019;;10.1523/jneurosci.0395-07.2007;;17634359;;pmc6672892;;pmc6672917;;17251419;;10.1523/jneurosci.3501-06.2007;;10.1523/jneurosci.3432-04.2004;;15537891;;pmc6730194;;10.1523/jneurosci.1643-04.2004;;pmc6729662;;15240813;;10.1038/nature04533;;16541076;;17245437;;10.1038/sj.emboj.7601507;;pmc1783448;;8637886;;pmc39809;;10.1073/pnas.93.6.2403;;10.1007/bf02780662;;7999308;;17182778;;pmc2856604;;10.1523/jneurosci.4504-06.2006;;pmc2846286;;16452662;;10.1523/jneurosci.3291-05.2006;;9811807;;10.1073/pnas.95.23.13363;;pmc33918;;10.1038/ncb1156;;15258590;;8700211;;10.1038/382180a0;;0008700211;;10.1523/jneurosci.4970-06.2007;;10.3410/f.1102046.558017;;pmc6672572;;17360908;;14752167;;10.1126/science.1094273;;pmc26733;;10.1073/pnas.96.5.2042;;10051591;;11932745;;10.1038/416535a;;pmc2855693;;16958113;;10.1002/ana.20953;;20946660;;pmc2964735;;10.1186/1471-2202-11-130;;12601712;;10.1002/ana.10507;;17542810;;10.1111/j.1471-4159.2006.04439.x;;16817866;;pmc1779824;;10.1111/j.1460-9568.2006.04805.x;;15917101;;10.1016/j.neurobiolaging.2004.10.004;;10.1038/nature01457;;12621436;;10.1038/news030303-7;;pmc3156817;;10.1038/ncomms1341;;21654636,"Pankiewicz et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci. May 2006;23(10):2635-47.;;Zeisel et al. Non-pharmacological Treatment for Alzheimer's Disease: A mind-brain approach. Non-pharmacological Treatment for Alzheimer's. Mar. 1999, p. 1-16.;;Westergard et al. The cellular prion protein (PrPc): Its physiological function and role in disease. Biochim Biophys Acta. Jun. 2007; 1772(6): 629-644.;;Hirsch et al. PrPc signalling in neurons: From basics to clinical challenges. Biochimie, in press, available online (Jun. 18, 2014) pp. 1-10.;;Hampel et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol. Dec. 2011;95(4):718-28.;;Vickers. A vaccine against Alzheimer's disease: developments to date. Drugs Aging. 2002;19(7):487-94. Review.;;Perrin et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. Oct. 15, 2009;461(7266):916-22.;;Golabek et al. Abstract Only. Amyloid beta binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett. May 19, 1995;191(1-2):79-82.;;Parkin, et al., ""Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein,"" PNAS 104(26):11062-11067, The National Academy of Sciences of the USA, United States (2007).;;Yehiely, F., et al., ""Identification of Candidate Proteins Binding to Prion Protein,"" Neurobiology of Disease 3:339-355, Academic Press, United States (1997).;;Baumann, F., et al., ""Lethal recessive myelin toxicity of prion protein lacking its central domain,"" EMBO J. 26:538-547, Nature Publishing Group, United Kingdom (Jan. 2007).;;Büeler, H., et al., ""Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein,"" Nature 356: 577-582, Nature Publishing Group, United Kingdom (1992).;;Chapman, P., et al., ""Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice,"" Nat. Neurosci. 2: 271-276, Nature Publishing Group, United States (1999).;;Chen, G.,et al., ""A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease,"" Nature 408: 975-979, Nature Publishing Group, United Kingdom (2000).;;Chromy, B., et al., ""Self-Assembly of abeta1-42 into Globular Neurotoxins,"" Biochemistry 42:12749-12760, American Chemical Society, United States (2003).;;Cleary, J., et al., ""Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function,"" Nat. Neurosci. 8:79-84, Nature Publishing Group, United States (2005).;;Fournier, A., et al., ""Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration,"" Nature 409: 341-346, Nature Publishing Group, United Kingdom (2001).;;Haass, C. and Selkoe, D.J., ""Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide,"" Nat. Rev. Mol. Cell Biol. 8:101-112, Nature Publishing Group, United Kingdom (Feb. 2007).;;Hardy, J. and Selkoe, D.J., ""The Amyloid Hypothesis of Alzheimer's disease: Progress and Problems on the Road to Therapeutics,"" Science 297:353-356, American Association for the Advancement of Science, United States (2002).;;Jankowsky, J., et al., ""Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmenation of a 42-specific gamma secretase,"" Hum. Mol. Genet. 13:159-170, IRL Press at Oxford University Press, United Kingdom (2004).;;Knobloch, M., et al., ""Abeta Oligomer-Mediated Long-Term Potentiation Impairment Involves Protein Phosphatase 1-Dependent Mechanisms,"" J. Neurosci. 27:7648-7653, Society for Neuroscience, United States (Jul. 2007).;;Lacor, P., et al.,""Abeta Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's disease,"" J. Neurosci. 27:796-807, Society for Neuroscience, United States (Jan. 2007).;;Lacor, P., et al., ""Synaptic Targeting by Alzheimer's-Related Amyloid beta Oligomers,"" J. Neurosci. 24:10191-10200, Society for Neuroscience, United States (2004).;;Lee, J., et al., ""Nogo Receptor Antagonism Promotes Stroke Recovery by Enhancing Axonal Plasticity,"" J. Neurosci. 24:6209-6217, Society for Neuroscience, United States (2004).;;Lesné, S., et al., ""A specific amyloid-beta protein assembly in the brain impairs memory,"" Nature 440:352-357, Nature Publishing Group, United Kingdom (Mar. 2006).;;Li, A., et al., ""Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125,"" EMBO J. 26:548-558, Nature Publishing Group, United Kingdom (Jan. 2007).;;Lledo, P.-M., et al., ""Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus,"" Proc. Natl. Acad. Sci. U.S.A. 93:2403-2407, National Academy of Sciences, United States (1996).;;Manson, J., et al., ""129/Ola Mice Carrying a Null Mutation in PrP that abolishes mRNA Production are Developmentally Normal,"" Mol. Neurobiol. 8:121-127, Humana Press, United States (1994).;;Park, J., et al., ""Subcutaneous Nogo Receptor Removes Brain Amyloid-beta and Improves Spatial Memory in Alzheimer's Transgenic Mice,"" J. Neurosci. 26:13279-13286, Society for Neuroscience, United States (Dec. 2006).;;Park, J., et al., ""Alzheimer Precursor Protein Interaction with the Nogo-66 Receptor Reduces Amyloid-beta Plaque Deposition,"" J. Neurosci. 26:1386-1395, Society for Neuroscience, United States (Feb. 2006).;;Prusiner, S., ""Prions,"" Proc. Natl. Acad. Sci. U.S.A. 95:13363-13383, National Academy of Sciences, United States (1998).;;Rajagopalan, S., et al., ""Neogenin mediates the action of repulsive guidance molecule,"" Nat. Cell Biol. 6: 756-762, Macmillan Magazines Ltd., United Kingdom (2004).;;Riek, R., et al., NMR structure of the mouse prion protein domain PrP(121-231), Nature 382:180-82, Nature Publishing Group, United Kingdom (1996).;;Shankar, G., et al., ""Natural Oligomers of the Alzheimer Amyloid-beta Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway,"" J. Neurosci. 27:2866-2875, Society for Neuroscience, United States (Mar. 2007).;;Solforosi, L., et al., ""Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis in Vivo,"" Science 303: 1514-1516, American Association for the Advancement of Science, United States (2004).;;Viles, J., et al., ""Copper binding to the prion protein: Structural implications of four identical cooperative binding sites,"" Proc. Natl. Acad. U.S.A. 96:2042-47, National Academy of Sciences, United States (1999).;;Walsh, D., et al., ""Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo,"" Nature 416:535-539, Nature Publishing Group, United Kingdom (2002).;;Wang, X., et al., ""Delayed Nogo Receptor Therapy Improves Recovery from Spinal Cord Contusion,"" Ann. Neurol. 60:540-549, Wiley-Liss, United States (Nov. 2006).;;International Search Report for International Application No. PCT/US08/05427, mailed on Sep. 19, 2008, ISA/US, Alexandria, Virginia, United States.;;Chung E., et al., ""Anti-PrPc monoclonal antibody infusion as a novel treatment for cognitive deficits in an alzheimer's disease model mouse,"" BMC Neuroscience 11:130, BioMed Central Ltd., United Kingdom (2010).;;Dermaut, B., et al., ""PRNP Val129 Homozygosity Increases Risk for Early Onset Alzheimer's Disease,"" Ann. Neurol. 53:409-12, Wiley-Liss, Inc., United States(2003).;;Filesi, I., et al., ""Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrPSc formation,"" J. Neurochemistry 101:1516-26, Int'l Society for Neurochemistry, United Kingdom (2007).;;McNeill, A., ""A Molecular Analysis of Prion Protein Expression in Alzheimer's Disease,"" McGill J. Medicine 8:7-14, MJM, Canada (2004).;;Pankiewicz, J., et al., ""Clearance and prevention of prion infection in cell culture by anti-PrP antibodies,"" Eur. J. Neurosci. 23:2635-47, Federation of European Neuroscience Societies and Blackwell Publishing, Ltd., United Kingdom (2006).;;Schwarze-Eicker, K., et al., ""Prion protein (PrPc) promotes B-amyloid plaque formation,"" Neurobiology of Aging 26:1 177-82, Elsevier Inc., United States (2005).;;White, A.R., et al., ""Monoclonal antibodies inhibit prion replication and delay the development of prion disease,"" Nature 422:80-83, Nature Publishing Group, United Kingdom (2003).;;International Preliminary Report on Patentability for International Application No. PCT/US2008/005427, issued Oct. 27, 2009, International Bureau, Geneva, Switzerland.;;Supplementary European Search Report for European Application No. EP 08743351, completed Dec. 9, 2011, EPO, The Hague, Netherlands.;;Freir D.B., et al., ""Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites,"" Nature Communications 2:336:1-9, Macmillian Publishers Ltd., United States (2011).",ACTIVE
4,CA,A1,CA 2719878 A1,126-535-479-505-57X,2008-11-06,2008,CA 2719878 A,2008-04-28,US 92660507 P;;US 2008/0005427 W,2007-04-26,PRION PROTEIN AS A RECEPTOR FOR AMYLOID-BETA OLIGOMERS,"The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinittions, as well as methods of identifying molecules that could function as PrPc antagonists.",UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,,https://lens.org/126-535-479-505-57X,Patent Application,no,0,0,8,8,18,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,C07K16/00;;G01N33/53,,0,0,,,,INACTIVE
5,EP,A4,EP 2152744 A4,152-116-275-596-816,2012-02-15,2012,EP 08743351 A,2008-04-28,US 2008/0005427 W;;US 92660507 P,2007-04-26,PRION PROTEIN AS A RECEPTOR FOR AMYLOID-BETA OLIGOMERS,,UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,,https://lens.org/152-116-275-596-816,Search Report,no,1,0,8,8,0,A61K2039/505;;C07K2317/34;;C07K2317/76;;C07K16/2872;;A61P25/28;;A61K2039/505;;C07K2317/34;;C07K2317/76;;C07K16/2872;;A61K39/3955,C07K16/28;;C07K16/00;;G01N33/53,,7,6,031-616-215-173-831;;153-215-404-527-703;;003-156-271-477-135;;013-804-064-203-989;;007-242-190-246-438;;033-827-653-754-700,17542810;;10.1111/j.1471-4159.2006.04439.x;;15917101;;10.1016/j.neurobiolaging.2004.10.004;;10.1038/nature01457;;12621436;;10.1038/news030303-7;;pmc3156817;;10.1038/ncomms1341;;21654636;;10.1016/j.pep.2004.09.013;;15596355;;19242475;;10.1038/nature07761;;pmc2748841,"ILARIA FILESI ET AL: ""Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP Sc formation"", JOURNAL OF NEUROCHEMISTRY, vol. 101, no. 6, 11 January 2007 (2007-01-11), pages 1516 - 1526, XP055001964, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.2006.04439.x;;SCHWARZE-EICKER K ET AL: ""Prion protein (PrP<c>) promotes beta-amyloid plaque formation"", NEUROBIOLOGY OF AGING, vol. 26, no. 8, 1 August 2005 (2005-08-01), TARRYTOWN, NY, US, pages 1177 - 1182, XP004904946, ISSN: 0197-4580, DOI: 10.1016/J.NEUROBIOLAGING.2004.10.004;;WHITE ANTHONY R ET AL: ""Monoclonal antibodies inhibit prion replication and delay the development of prion disease"", NATURE, vol. 422, no. 6927, 6 March 2003 (2003-03-06), NATURE PUBLISHING GROUP, LONDON, GB, pages 80 - 83, XP002275535, ISSN: 0028-0836, DOI: 10.1038/NATURE01457;;DARRAGH B. FREIR ET AL: ""Interaction between prion protein and toxic amyloid [beta] assemblies can be therapeutically targeted at multiple sites"", NATURE COMMUNICATIONS, vol. 2, 7 June 2011 (2011-06-07), pages 336, XP055165531, DOI: 10.1038/ncomms1341;;STUKE A W ET AL: ""Tetracycline-regulated highly inducible expression of the human prion protein in murine 3T3 cells"", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 39, no. 1, 1 January 2005 (2005-01-01), pages 8 - 17, XP004680011, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2004.09.013;;LAURÉN JUHA ET AL: ""Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers"", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 457, no. 7233, 26 February 2009 (2009-02-26), pages 1128 - 1132, XP009120514, ISSN: 0028-0836, DOI: 10.1038/NATURE07761;;See also references of WO 2008134034A1",DISCONTINUED
6,WO,A1,WO 2008/134034 A1,173-971-932-006-273,2008-11-06,2008,US 2008/0005427 W,2008-04-28,US 92660507 P,2007-04-26,PRION PROTEIN AS A RECEPTOR FOR AMYLOID-BETA OLIGOMERS,"The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinittions, as well as methods of identifying molecules that could function as PrP c antagonists.",UNIV YALE;;STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,,https://lens.org/173-971-932-006-273,Patent Application,yes,2,16,8,8,0,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,C07K16/00;;G01N33/53,,13,11,023-797-140-306-411;;039-409-197-242-889;;132-850-463-050-678;;063-230-321-779-481;;027-197-300-418-567;;008-880-878-442-763;;056-075-273-105-472;;012-909-312-770-590;;059-008-823-209-233;;047-187-420-589-746;;013-184-902-837-362,10.1073/pnas.192559699;;12391321;;pmc137867;;pmc101847;;10.1093/nar/30.7.1664;;11917028;;12145662;;10.1038/ng944;;12097900;;10.1038/418038a;;10.1016/s0006-291x(02)02013-2;;12200148;;10.1126/stke.2002.147.pl13;;12198178;;12099702;;10.1016/s0006-291x(02)00736-2;;10.1016/s0014-5793(02)02860-0;;12096714;;10.1073/pnas.152327299;;pmc126604;;12096193;;11972060;;10.1073/pnas.092143499;;pmc122899;;pmc6672917;;17251419;;10.1523/jneurosci.3501-06.2007,"See also references of EP 2152744A4;;CALEGARI ET AL., PROC NATL ACAD SCI USA, vol. 99, 2002, pages 14236 - 14240;;ZHOU ET AL., NUCLEIC ACIDS RES, vol. 30, 2002, pages 1664 - 1669;;LEWIS ET AL., NAT GENET, vol. 32, 2002, pages 107 - 108;;MCCAFFREY ET AL., NATURE, vol. 418, 2002, pages 38 - 39;;BERTRAND ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 296, 2002, pages 1000 - 1004;;LASSUS ET AL., SCI STKE, vol. 2002, pages 147;;LEIRDAL ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 295, 2002, pages 744 - 748;;HOHJOH, FEBS LETT, vol. 521, 2002, pages 195 - 199;;YANG ET AL., PROC NATL ACAD SCI USA, vol. 99, 2002, pages 9942 - 9947;;DONZEET ET AL., NUCLEIC ACIDS RES, vol. 30, 2002, pages E46;;YU ET AL., PROC NATL ACAD SCI USA, vol. 99, 2002, pages 6047 - 6052;;LACOR ET AL., J NEUROSCI, vol. 27, 2007, pages 796 - 807",PENDING
7,CA,C,CA 2719878 C,064-350-605-735-07X,2017-08-29,2017,CA 2719878 A,2008-04-28,US 92660507 P;;US 2008/0005427 W,2007-04-26,PRION PROTEIN AS A RECEPTOR FOR AMYLOID-BETA OLIGOMERS,"The invention provides methods of inhbiting suppression of long term potentiation, improving acute memory re-tention and spatial memory performance and treating Alzheimer's disease by administration of a PrPc antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinit-tions, as well as methods of identifying molecules that could function as PrP c antagonists.",UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,,https://lens.org/064-350-605-735-07X,Granted Patent,no,0,0,8,8,18,A61K2039/505;;C07K2317/34;;C07K2317/76;;C07K16/2872;;A61P25/28;;A61K2039/505;;C07K2317/34;;C07K2317/76;;C07K16/2872;;A61K39/3955,A61K39/395;;A61K31/7088;;A61K38/17;;A61P25/28;;G01N33/50;;G01N33/68,,0,0,,,,INACTIVE
8,US,A1,US 2016/0176972 A1,016-964-963-730-960,2016-06-23,2016,US 201514974442 A,2015-12-18,US 201514974442 A;;US 59753510 A;;US 2008/0005427 W;;US 92660507 P,2007-04-26,Prion Protein as a Receptor for Amyloid-Beta Oligomers,"The invention provides methods of inhibiting suppression of long term potentiation, improving acute memory retention and spatial memory performance and treating Alzheimer's disease by administration of a PrP c antagonist or combinations thereof. Additionally, this invention provides pharmaceutical kits comprising, and methods for making and using, such combinations, as well as methods of identifying molecules that could function as PrP c antagonists.",UNIV YALE,STRITTMATTER STEPHEN M;;LAUREN JUHA;;GIMBEL DAVID,YALE UNIVERSITY (2009-11-16),https://lens.org/016-964-963-730-960,Patent Application,yes,0,1,8,8,18,A61K39/3955;;A61K2039/505;;A61K2039/505;;A61P25/28;;C07K16/2872;;C07K16/2872;;C07K2317/34;;C07K2317/34;;C07K2317/76;;C07K2317/76,C07K16/28;;A61K39/395,,0,0,,,,DISCONTINUED
9,US,B2,US 9879308 B2,031-384-313-762-330,2018-01-30,2018,US 201414586577 A,2014-12-30,US 201414586577 A;;US 201314070444 A;;US 201261721183 P,2012-11-01,Apparatus for ex vivo microfluidic analysis of biologic samples,"Systems and methods for culturing and monitoring, ex vivo, pharmacologic and metabolic response in a biological sample, including receiving at a fluidic apparatus the biological sample retrieved from the patient, retaining the biological sample within a channel of the fluidic apparatus, providing for the culture of the biological sample within the channel of the fluidic apparatus, flowing a fluid past the biological sample, retrieving and analyzing the fluid to determine a pharmacologic and/or metabolic response of the sample.",CHARLES STARK DRAPER LABORATORY INC,HOLTON ANGELA;;GIMBEL ALLA;;LANDIS DAVID;;SPENCER ABIGAIL,THE CHARLES STARK DRAPER LABORATORY INC (2014-01-15),https://lens.org/031-384-313-762-330,Granted Patent,yes,12,1,6,6,0,C12M23/16;;G01N33/5082;;G01N2510/00;;B01L3/502761;;B01L2200/0668;;B01L2400/0487;;B01L2400/086;;G01N33/5008;;C12M23/16;;G01N33/5082;;G01N2510/00;;B01L3/502761;;B01L2200/0668;;B01L2400/0487;;B01L2400/086;;C12Q1/68,G01N33/50;;B01L3/00;;C12M3/06;;C12Q1/68,,10,5,052-934-670-414-233;;037-220-493-883-400;;012-843-870-486-309;;032-113-634-002-844;;027-089-202-689-023,10.1007/s10439-011-0428-9;;21997391;;22160577;;10.1007/s10439-011-0480-5;;10.1038/nbt1208-1345;;19060870;;10.1039/b802395f;;18818801;;pmc2560179;;pmc4017600;;23358873;;10.1007/s10544-012-9734-8,"Doran, Marianne, Fine-Needle Aspiration Biopsy for Ocular and Orbital Tumors, Oncology, EyeNet, pp. 37-39, Jul. 2012.;;FBNA. Procedure/diagnostic tests: interventional radiology. Clinical Center national Institutes of Health, pp. 1-5, 2010.;;Hattersley et al., A Microfluidic System for Testing the Responses of Head and Neck Squamous Cell Carcinoma Tissue Biopsies to Treatment with Chemotherapy Drugs, Annals of biomedical engineering, vol. 40, No. 6, pp. 1277-1288 (Jun. 2012).;;International Search Report and Written Opinion dated Jan. 31, 2014 in PCT Application No. PCT/US2013/068168 (9 pages).;;Kim, et al. In-Situ Synthesized and Patterned Nanowire Arrays in Microfluidic Channel for Particle Trapping and Cell Lysis Applications, 15th International Conference on Miniaturized Systems for Chemistry and Life Sciences, pp. 1789-1791, Oct. 2011.;;Prot et al, The Current Status of Alternative to Animal Testing and Predictive Toxicology Methods Using Liver Microfluidic Biochips, Annals of biomedical engineering, vol. 40, No. 6, pp. 1228-1243 (Jun. 2012).;;Sorger, Peter K., Microfluidics closes in on point-of-care assays, Nature Biotechnology, vol. 26, No. 12, pp. 1345-1346 (Dec. 2008).;;U.S. Office Action in U.S. Appl. No. 14/070,444 dated Mar. 4, 2015.;;Vickerman et al., Design, fabrication and implementation of a novel multi-parameter control microfluidic platform for three-dimensional cell culture and real-time imaging, Lab on a Chip, vol. 8, No. 9, pp. 1468-1477 (Jul. 2008).;;Zhang et al, Microfluidics and cancer: are we there yet?, Biomed Microdevices, vol. 15, No. 4, pp. 595-609 (Jan. 2013).",ACTIVE
10,EP,A3,EP 1072482 A3,009-980-180-849-03X,2001-09-05,2001,EP 00202329 A,2000-07-03,US 36306199 A,1999-07-29,Frontal air bag system,A frontal air bag system (10) for a vehicle (12) including an inflator (40) mounted to vehicle structure and a frontal air bag (24) operatively connected to the inflator (40) and mounted to an A-pillar (20) and header (20a) of the vehicle (12). The frontal air bag system (10) also includes a wrap air bag (28) at least partially continuous with the frontal air bag (24). The frontal air bag (24) and the wrap air bag (28) are mounted to an A-pillar (20) of the vehicle (12). The frontal air bag (24) and the wrap air bag (28) are inflated by the inflator (40) and the frontal air bag (24) is extended downward and in front of an occupant (23) seated in the vehicle (12) and the wrap air bag (28) is extended above the frontal air bag (24).,DELPHI TECH INC,VIANO DAVID C;;GIMBEL HANS PETER;;GOPAL MADANA,,https://lens.org/009-980-180-849-03X,Search Report,yes,5,0,3,3,0,B60R21/213;;B60R21/231;;B60R21/23138;;B60R21/232;;B60R2021/0004;;B60R2021/0006;;B60R2021/0009;;B60R2021/0018;;B60R2021/0072;;B60R2021/23107;;B60R2021/23123;;B60R2021/23382;;B60R2021/23386;;B60R2021/2612;;B60R21/231;;B60R2021/23123;;B60R2021/23386;;B60R2021/0018;;B60R2021/0009;;B60R21/232;;B60R2021/0004;;B60R21/213;;B60R21/23138;;B60R2021/23382;;B60R2021/0006;;B60R2021/0072;;B60R2021/2612;;B60R2021/23107,B60R21/00;;B60R21/16;;B60R21/213;;B60R21/231;;B60R21/233;;B60R21/2338;;B60R21/26;;B60R21/261,,1,0,,,"""UN AIRBAG AU PLAFOND"", REVUE AUTOMOBILE,CH,HALLWAG S.A. BERNE, vol. 91, no. 41, 3 October 1996 (1996-10-03), pages 7, XP000625495, ISSN: 0035-0761",DISCONTINUED
11,EP,A2,EP 1072482 A2,141-702-950-806-948,2001-01-31,2001,EP 00202329 A,2000-07-03,US 36306199 A,1999-07-29,Frontal air bag system,A frontal air bag system (10) for a vehicle (12) including an inflator (40) mounted to vehicle structure and a frontal air bag (24) operatively connected to the inflator (40) and mounted to an A-pillar (20) and header (20a) of the vehicle (12). The frontal air bag system (10) also includes a wrap air bag (28) at least partially continuous with the frontal air bag (24). The frontal air bag (24) and the wrap air bag (28) are mounted to an A-pillar (20) of the vehicle (12). The frontal air bag (24) and the wrap air bag (28) are inflated by the inflator (40) and the frontal air bag (24) is extended downward and in front of an occupant (23) seated in the vehicle (12) and the wrap air bag (28) is extended above the frontal air bag (24).,DELPHI TECH INC,VIANO DAVID C;;GIMBEL HANS PETER;;GOPAL MADANA,,https://lens.org/141-702-950-806-948,Patent Application,yes,0,1,3,3,0,B60R21/231;;B60R21/231;;B60R21/213;;B60R21/213;;B60R21/23138;;B60R21/23138;;B60R21/232;;B60R21/232;;B60R2021/0004;;B60R2021/0004;;B60R2021/0006;;B60R2021/0006;;B60R2021/0009;;B60R2021/0009;;B60R2021/0018;;B60R2021/0018;;B60R2021/0072;;B60R2021/0072;;B60R2021/23107;;B60R2021/23107;;B60R2021/23123;;B60R2021/23123;;B60R2021/23382;;B60R2021/23382;;B60R2021/23386;;B60R2021/23386;;B60R2021/2612;;B60R2021/2612,B60R21/00;;B60R21/16;;B60R21/213;;B60R21/231;;B60R21/233;;B60R21/2338;;B60R21/26;;B60R21/261,,0,0,,,,DISCONTINUED
12,US,A,US 6116644 A,159-997-086-328-721,2000-09-12,2000,US 36306199 A,1999-07-29,US 36306199 A;;US 6591298 A,1998-04-24,Frontal air bag system,A frontal air bag system for a vehicle including an inflator mounted to vehicle structure and a frontal air bag operatively connected to the inflator and mounted to an A-pillar and header of the vehicle. The frontal air bag system also includes a wrap air bag at least partially continuous with the frontal air bag. The frontal air bag and the wrap air bag are mounted to an A-pillar of the vehicle. The frontal air bag and the wrap air bag are inflated by the inflator and the frontal air bag is extended downward and in front of an occupant seated in the vehicle and the wrap air bag is extended above the frontal air bag.,DELPHI TECH INC,VIANO DAVID CHARLES;;GIMBEL HANS-PETER;;GOPAL MADANA,DELPHI TECHNOLOGIES INC (1999-10-06),https://lens.org/159-997-086-328-721,Granted Patent,yes,5,30,3,3,0,B60R21/231;;B60R21/231;;B60R21/213;;B60R21/213;;B60R21/23138;;B60R21/23138;;B60R21/232;;B60R21/232;;B60R2021/0004;;B60R2021/0004;;B60R2021/0006;;B60R2021/0006;;B60R2021/0009;;B60R2021/0009;;B60R2021/0018;;B60R2021/0018;;B60R2021/0072;;B60R2021/0072;;B60R2021/23107;;B60R2021/23107;;B60R2021/23123;;B60R2021/23123;;B60R2021/23382;;B60R2021/23382;;B60R2021/23386;;B60R2021/23386;;B60R2021/2612;;B60R2021/2612,B60R21/00;;B60R21/16;;B60R21/213;;B60R21/231;;B60R21/233;;B60R21/2338;;B60R21/26;;B60R21/261,280/743.1;;280/743.2;;280/728.2,1,0,,,"U.S. application No. 09/065,912, Viano et al., filed Apr. 24, 1998.",EXPIRED
13,US,A1,US 2017/0361508 A1,147-220-604-326-497,2017-12-21,2017,US 201515534827 A,2015-12-09,US 201515534827 A;;US 201462090265 P;;US 201462090337 P;;US 2015/0064795 W,2014-12-10,POLYMER MICROWEDGES AND METHODS OF MANUFACTURING SAME,"A mold for casting a micro-scale dry adhesive structure includes an upper surface including a first cavity having a first depth, a negative pattern for an array of micro-scale structures defined in a surface of the first cavity, and at least one second cavity having a second depth defined in the cavity outside of the negative pattern for the array of micro-scale structures, the at least one second cavity defining a negative pattern for a standoff of the micro-scale dry adhesive structure.",CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LEBLANC JOHN;;GIMBEL ALLA,THE CHARLES STARK DRAPER LABORATORY INC (2017-06-07),https://lens.org/147-220-604-326-497,Patent Application,yes,4,5,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,B29C39/26;;B29C33/38;;B29C33/58;;B29C37/00;;B29C39/02;;B29K75/00;;B29K105/00;;B29L31/48,,0,0,,,,DISCONTINUED
14,US,A1,US 2017/0367418 A1,175-736-559-814-485,2017-12-28,2017,US 201515534907 A,2015-12-09,US 201515534907 A;;US 201462090337 P;;US 201462090265 P;;US 2015/0064791 W,2014-12-10,POLYMER MICROWEDGES AND METHODS OF MANUFACTURING SAME,A mold for casting a micro-scale structure includes an upper surface including a first cavity having a first depth. A negative pattern for an array of micro-scale structures is defined in a surface of the first cavity. The mold includes at least one second cavity having a second depth defined in the cavity outside of the negative pattern for the array of micro-scale structures. The at least one second cavity defines a negative pattern for a standoff of the micro-scale structure. A fabric retaining frame is disposed in the first cavity.,CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LEBLANC JOHN;;GIMBEL ALLA,THE CHARLES STARK DRAPER LABORATORY INC (2017-06-07),https://lens.org/175-736-559-814-485,Patent Application,yes,0,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,A41D19/015;;B29C33/38;;B29C33/42;;B29C39/02;;B29C39/10;;B29C45/37;;B29D99/00;;B29L31/48,,0,0,,,,ACTIVE
15,US,B2,US 10791779 B2,008-697-742-463-834,2020-10-06,2020,US 201515534907 A,2015-12-09,US 201515534907 A;;US 201462090337 P;;US 201462090265 P;;US 2015/0064791 W,2014-12-10,Polymer microwedges and methods of manufacturing same,A mold for casting a micro-scale structure includes an upper surface including a first cavity having a first depth. A negative pattern for an array of micro-scale structures is defined in a surface of the first cavity. The mold includes at least one second cavity having a second depth defined in the cavity outside of the negative pattern for the array of micro-scale structures. The at least one second cavity defines a negative pattern for a standoff of the micro-scale structure. A fabric retaining frame is disposed in the first cavity.,CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LEBLANC JOHN;;GIMBEL ALLA,THE CHARLES STARK DRAPER LABORATORY INC (2017-06-07),https://lens.org/008-697-742-463-834,Granted Patent,yes,72,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,A41D19/015;;B29C33/38;;B29C33/42;;B29C33/58;;B29C37/00;;B29C39/02;;B29C39/10;;B29C39/26;;B29C45/37;;B29C59/02;;B29D99/00;;B29K75/00;;B29K105/00;;B29L31/48,,10,4,110-216-634-871-803;;097-382-690-906-008;;072-813-371-754-523;;079-460-960-342-184,pmc2817158;;10.1098/rsif.2009.0048;;19324664;;10.1021/la204040p;;22375683;;10.1021/am4052393;;24527733;;10.1073/pnas.0900323106;;pmc2667085;;19304801,"Parness et al., A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality and long life, Mar. 18, 2009, Journal of the Royal Society (2009) 6, 1223-1232 (Year: 2009).;;John Mangels, University of Akron's research into gecko's natural stickiness may pay off in companies and products, The Plain Dealer, Sep. 29, 2012 (Year: 2012).;;Jin et al., Design and Fabrication of Gecko-Inspired Adhesives, Feb. 29, 2012, Langmuir (Year: 2012).;;Boris Luu, Processing PDMS Gecko Tape Using Isopore Filters and Silicon Wafer Templates, Jun. 6, 2011, California Polytechnic State University (Year: 2011).;;International Search Report and Written Opinion for International Application No. PCT/US2015-064795 dated Dec. 29, 2016.;;YUE WANG, HONG HU, JINYOU SHAO, YUCHENG DING: ""Fabrication of Well-Defined Mushroom-Shaped Structures for Biomimetic Dry Adhesive by Conventional Photolithography and Molding"", ACS APPLIED MATERIALS & INTERFACES, AMERICAN CHEMICAL SOCIETY, US, vol. 6, no. 4, 26 February 2014 (2014-02-26), US, pages 2213 - 2218, XP055253754, ISSN: 1944-8244, DOI: 10.1021/am4052393;;Hoon Eui Jeong et al: “A Nontransferring Dry Adhesive with Hierarchical Polymer Nanohairs”, Proceedings of the National Academy of Sciences of the United States of America, Apr. 7, 2009, pp. 5639-5644, XP055253908, United States, DOI: 10.1073/pnas.0900323106.;;International Search Report and Written Opinion for International Application No. PCT/US2015-064791 dated Mar. 17, 2016.;;International Search Report and Written Opinion for International Application No. PCT/US2015-064798 dated Jun. 15, 2016.;;Office Action from European Application No. 15830916.1 dated Oct. 24, 2019.",ACTIVE
16,KR,A,KR 20170118698 A,005-337-683-711-202,2017-10-25,2017,KR 20177019107 A,2015-12-09,US 201462090337 P;;US 201462090265 P;;US 2015/0064795 W,2014-12-10,POLYMER MICROWEDGES AND METHODS OF MANUFACTURING SAME,"마이크로스케일 건식 접착성 구조체를 캐스팅하기 위한 몰드는 제 1 깊이를 갖는 제 1 캐비티, 상기 제 1 캐비티의 표면에서 규정된 마이크로스케일 구조체 배열에 대한 네거티브 패턴, 및 상기 마이크로스케일 구조체 배열에 대한 네거티브 패턴의 캐비티 외부에서 규정된 제 2 깊이를 갖는 적어도 1개의 제 2 캐비티를 포함하고, 상기 적어도 1개의 제 2 캐비티는 상기 마이크로스케일 건식 접착성 구조체의 스탠드오프에 대한 네거티브 패턴을 규정한다.",CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA,,https://lens.org/005-337-683-711-202,Patent Application,no,0,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,B29C33/42;;B29C33/38;;B29C37/00;;B29C39/02;;B29C39/10;;B29C45/37;;B29C59/02;;B29L31/48;;B81C99/00,,0,0,,,,PENDING
17,EP,A1,EP 3230033 A1,094-254-897-756-638,2017-10-18,2017,EP 15819957 A,2015-12-09,US 201462090265 P;;US 201462090337 P;;US 2015/0064791 W,2014-12-10,POLYMER MICROWEDGES AND METHODS OF MANUFACTURING SAME,,CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA,,https://lens.org/094-254-897-756-638,Patent Application,yes,0,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,B29C33/42;;A41D19/00;;B29C33/12;;B29C33/38;;B29C37/00;;B29C39/02;;B29C39/10,,0,0,,,,DISCONTINUED
18,KR,A,KR 20170118699 A,057-465-972-352-325,2017-10-25,2017,KR 20177019126 A,2015-12-09,US 201462090265 P;;US 201462090337 P;;US 2015/0064791 W,2014-12-10,POLYMER MICROWEDGES AND METHODS OF MANUFACTURING SAME,마이크로스케일 구조체를 캐스팅하는 몰드가 제 1 깊이를 갖는 제 1 캐비티를 포함하는 상면을 포함한다. 마이크로스케일 구조체의 어레이에 대한 네가티브 패턴이 상기 제 1 캐비티의 표면에 규정된다. 상기 몰드는 상기 마이크로스케일 구조체의 어레이에 대한 네가티브 패턴 외부의 캐비티에 규정된 제 2 깊이를 갖는 적어도 하나의 제 2 캐비티를 포함한다. 상기 적어도 하나의 제 2 캐비티는 상기 마이크로스케일 구조체의 스탠드오프에 대한 네가티브 패턴을 규정한다. 패브릭 고정 프레임이 상기 제 1 캐피티에 배치된다.,CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA,,https://lens.org/057-465-972-352-325,Patent Application,no,0,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,B29C33/42;;A41D19/015;;B29C33/38;;B29C37/00;;B29C39/02;;B29C39/10;;B29C45/37;;B29C59/02;;B81C99/00,,0,0,,,,PENDING
19,EP,A2,EP 3230035 A2,061-918-757-506-786,2017-10-18,2017,EP 15871300 A,2015-12-09,US 201462090337 P;;US 201462090265 P;;US 2015/0064795 W,2014-12-10,MOLD FOR CASTING POLYMER MICROWEDGES AND METHOD OF CASTING POLYMER MICROWEDGES,,CHARLES STARK DRAPER LABORATORY INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA,,https://lens.org/061-918-757-506-786,Patent Application,yes,0,0,14,21,0,A41D19/01564;;B29C33/3842;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29C45/372;;B29C2059/023;;B29K2891/00;;B29K2863/00;;B29L2031/4864;;B29D99/0067;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/424;;B29C39/10;;B29C33/3842;;A41D19/01564;;B29C37/0053;;B29C39/026;;B29C45/372;;B81C99/0085;;B29C2059/023;;B29K2863/00;;B29K2891/00;;B29L2031/4864;;B29C45/372;;B29C33/424;;B29C37/0053;;B29C39/026;;B29C39/10;;B29D99/0067;;B29K2891/00;;B29K2863/00;;B29C33/3842;;B29C2059/023;;A41D19/01564;;B29C33/58;;B29C39/26;;B29K2075/00;;B29K2105/0097,B29C33/38;;A41D19/015;;B29C33/42;;B29C37/00;;B29C39/02;;B29C39/10;;B29C45/37;;B29C59/02;;B29D99/00;;B29L31/48,,0,0,,,,DISCONTINUED
20,KR,A,KR 20170130352 A,199-751-256-279-477,2017-11-28,2017,KR 20177019091 A,2015-12-09,US 201462090265 P;;US 2015/0064798 W,2014-12-10,METAL MOLDS FOR POLYMER MICROWEDGE FABRICATION,"마이크로스케일 건식 접착제 구조체를 캐스팅하기 위한 금속 몰드를 형성하는 방법은 도금 고정 장치에 마이크로스케일 건식 접착체 구조체를 포함하는 재료의 마스터 패치를 고정시키는 단계, 상기 재료의 패치에 상기 금속 몰드를 전기 주조하는 단계, 및 재료의 패치 및 상기 도금 고정 장치로부터 상기 금속 몰드를 제거하는 단계를 포함한다.",CHARLES STARK DRAPER LABORATORY INC;;MICROCONTINUUM INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA;;SLAFER W DENNIS;;MARTIN B DIANE,,https://lens.org/199-751-256-279-477,Patent Application,no,0,0,7,21,0,B23P15/24;;B29C33/307;;B29C33/3842;;B23P15/00;;B23P15/00;;B23P15/24;;B23P15/24;;B29C33/3842;;B29C33/42;;B29C33/42;;B29C33/42;;B29C33/424;;B29C33/424;;B29C33/68;;B29C39/026;;B29C39/026;;B29K2905/00;;B29K2905/00;;B29K2905/00;;B81C99/0085;;B81C99/0085;;C25D1/00;;C25D1/00;;C25D1/003;;C25D1/10;;C25D1/22;;C25D1/22;;C25D5/34,B29C33/38;;B23P15/24;;B29C33/42;;B81C99/00;;C25D1/00,,0,0,,,,PENDING
21,EP,A2,EP 3230034 A2,116-540-329-657-598,2017-10-18,2017,EP 15830916 A,2015-12-09,US 201462090265 P;;US 2015/0064798 W,2014-12-10,METAL MOLDS FOR POLYMER MICROWEDGE FABRICATION,,CHARLES STARK DRAPER LABORATORY INC;;MICROCONTINUUM INC,CARTER DAVID J;;SRIRAM TIRUNELVELI S;;KUMAR PARSHANT;;MORRIS CLAYTON;;MCFARLAND WILLIAM W;;COOK EUGENE H;;LE BLANC JOHN;;GIMBEL ALLA;;SLAFER W DENNIS;;MARTIN B DIANE,,https://lens.org/116-540-329-657-598,Patent Application,yes,1,0,7,21,0,B23P15/24;;B29C33/307;;B29C33/3842;;B23P15/00;;B23P15/00;;B23P15/24;;B23P15/24;;B29C33/3842;;B29C33/42;;B29C33/42;;B29C33/42;;B29C33/424;;B29C33/424;;B29C33/68;;B29C39/026;;B29C39/026;;B29K2905/00;;B29K2905/00;;B29K2905/00;;B81C99/0085;;B81C99/0085;;C25D1/00;;C25D1/00;;C25D1/003;;C25D1/10;;C25D1/22;;C25D1/22;;C25D5/34,B29C33/42;;B23P15/00;;B29C33/38;;B29C37/00;;B29C39/02;;C25D1/00,,1,0,,,See also references of WO 2016094562A2,DISCONTINUED
